Session Abstract – PMWC 2020 Silicon Valley


The pharmaceutical industry is applying a data science approach combined with active machine learning in various areas which include the integration of experimental work and computational modeling, automation, big data analytics, and informatics. This session will focus on pharma preparations and applications of AI and Machine Learning across drug discovery and development. Various examples will demonstrate how pharma is harnessing the opportunity of large data sets to predict and improve translation of preclinical findings to the specific human disease conditions to be evaluated in clinical studies.

 Session Chair Profile

M.D., Ph.D., Senior Vice President, Translational Discovery & Chief Evangelist, Recursion, Recursion Pharmaceuticals

Biography
Dr. Alfa is Senior Vice President, Translational Discovery and Chief Evangelist at Recursion Pharma where he manages Early Commercial strategy for Recursion’s discovery portfolio and evangelism of Recursion’s mission to decode biology to radically improve lives. Prior to Recursion, Dr. Alfa trained in science and medicine at Stanford University where he also worked closely with biotech startups at Stanford affiliated accelerator StartX. He has made scientific contributions spanning Neurosciences, Metabolism, and Genetics and is passionate about Recursion’s approach to unlocking drug discovery for human genetics using AI.


 Speaker Profile

Ph.D., Chief Scientific Officer, Camp4 Therapeutics

Biography
Dr. Iris Grossman is responsible for leading the company’s mission to discover how every gene in the human body responds to its environment through signaling, integrating multi-dimensional experimental data into CAMP4’s proprietary Gene Circuitry Platform. Under her direction, CAMP4 uses this platform to rapidly predict and validate druggable targets that control gene expression affecting a broad spectrum of diseases. Dr. Grossman also oversees the advancement of CAMP4’s drug pipeline and is integral to guiding the company’s partnering efforts. Dr. Grossman’s industry experience includes management roles at both large biopharmaceutical companies and start-ups, as well as consultancy firms. She has focused on leveraging genomic biomarkers, pharmacometrics and eHealth to augment the discovery, development and lifecycle management of biopharmaceutical assets. Prior to joining CAMP4, Dr. Grossman held roles of increasing responsibility at Teva, most recently serving as VP, Head of the Early Stage Clinical Development.


 Speaker Profile

CEO and Co-Founder, Repositive

Biography
Fiona is a bioinformatics scientist-turned entrepreneur. Having worked at Illumina developing tools for interpretation of next-generation sequencing data, Fiona realised the main bottleneck for genome interpretation and precision medicine is accessing the right data. Therefore, in 2013 Fiona founded DNAdigest as a charity to promote best practices for efficient and ethical data sharing, and in 2014, she co-founded Repositive to develop an online community platform and global exchange for genomic data. Fiona’s familiarity with the industry ensured that Repositive’s platforms would provide data access solutions while also respecting the industry's need for privacy, data governance and IP protection. This awareness was fundamental in securing £3M+ investment and support from early partners including AstraZeneca, Boehringer Ingelheim, XenTech and Shanghai LIDE Biotech. Fiona features on the 2018 WISE100 list, an index of the UK’s 100 most inspiring and influential women in social enterprise.


 Speaker Profile

Ph.D., CEO and Head of AI, Genesis Therapeutics

Biography
Evan Feinberg is a scientist and entrepreneur whose lifelong mission is to radically improve the way we discover new medicines. Dr. Feinberg started Genesis Therapeutics, an a16z-funded, AI-driven drug discovery company, to do just that. Before graduate school, Dr. Feinberg studied Applied Physics as an undergraduate at Yale while working on carbon nanotubes as cancer drug delivery agents at Sloan-Kettering. After grappling with his own physical disability, he experienced first-hand the limits of our current pharmacopeia. At Stanford, Evan invented novel neural network architectures for chemistry while working with Prof. Vijay Pande; their paper on PotentialNet is now the fifth-most read paper in 2019 in ACS Central Science. Dr. Feinberg completed his graduate career while consulting for Merck on deep learning and demonstrating step-change improvement in predicting the properties of drug candidates. Since then, Dr. Feinberg recruited elite software engineers and industry-leading biopharma veterans and drug developers to found Genesis.